The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Open accessAbstract
UNLABELLED: Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important in maintaining HIV latency and histone deacetylase inhibitors (HDACi) may reverse latency by activating HIV transcription from latently infected CD4+ T-cells. We performed a single arm, open label, proof-of-concept study in which vorinostat, a pan-HDACi, was administered 400 mg orally once daily for 14 days to 20 HIV-infected individuals on suppressive antiretroviral therapy (ART). The primary endpoint was change in cell associated unspliced (CA-US) HIV RNA in total CD4+ T-cells from blood at day 14. The study is registered at ClinicalTrials.gov (NCT01365065). Vorinostat was safe and well tolerated and there were no dose modifications or study drug discontinuations. CA-US HIV RNA in blood increased significantly in 18/20 patients (90%) with a median fold change from baseline to peak value of 7.4 (IQR 3.4, 9.1). CA-US RNA was significantly elevated 8 hours post drug and remained elevated 70 days after last dose. Significant early changes in expression of genes associated with chromatin remodeling and activation of HIV transcription correlated with the magnitude of increased CA-US HIV RNA. There were no statistically significant changes in plasma HIV RNA, concentration of HIV DNA, integrated DNA, inducible virus in CD4+ T-cells or markers of T-cell activation. Vorinostat induced a significant and sustained increase in HIV transcription from latency in the majority of HIV-infected patients. However, additional interventions will be needed to efficiently induce virus production and ultimately eliminate latently infected cells. TRIAL REGISTRATION: ClinicalTrials.gov NCT01365065.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796
Bioinformatics and Computational Biology Solutions Using R and Bioconductor
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0 · Cited by 3,289
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,083
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., et al. (1997) · Nature · doi:10.1038/387183a0 · Cited by 2,050
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F. A., Yassine-Diab, B., Boucher, G., Boulassel, M.-R., Ghattas, G., Brenchley, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1972 · Cited by 1,722
Self-citationAdministration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Self-citation
Cited by
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Søgaard, O. S., Graversen, M. E., Leth, S., Olesen, R., Brinkmann, C. R., Nissen, S. K., Kjaer, A. S., Schleimann, M. H., Denton, P. W., Hey-Cunningham, W. J., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005142 · Cited by 516
Self-citationInternational AIDS Society global scientific strategy: towards an HIV cure 2016
International AIDS Society Towards a Cure Working Group, Deeks, S. G., Lewin, S. R., Ross, A. L., Ananworanich, J., Benkirane, M., Cannon, P., Chomont, N., Douek, D., Lifson, J. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4108 · Cited by 425
Self-citationGetting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV
Kim, Y., Anderson, J. L., & Lewin, S. R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.004 · Cited by 414
Self-citationEx vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Laird, G. M., Bullen, C. K., Rosenbloom, D. I. S., Martin, A. R., Hill, A. L., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80142 · Cited by 391
Pollack, R. A., Jones, R. B., Pertea, M., Bruner, K. M., Martin, A. R., Thomas, A. S., Capoferri, A. A., Beg, S. A., Huang, S.-H., Karandish, S., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.03.008 · Cited by 370
“Latency reversal can be measured by detecting changes in levels of cell-associated (CA-) or plasma HIV-1 RNA (Archin et al., 2012; Elliott et al., 2014; Elliott et al., 2015; Leth et al., 2016; Rasmussen et al., 2014; Sogaard et al., 2015).”
The role of nanotechnology in the treatment of viral infections
Singh, L., Kruger, H. G., Maguire, G. E. M., Govender, T., & Parboosing, R. (2017) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936117713593 · Cited by 360
Targeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Yukl, S. A., Kaiser, P., Kim, P., Telwatte, S., Joshi, S. K., Vu, M., Lampiris, H., & Wong, J. K. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap9927 · Cited by 335
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 306
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
Nixon, C. C., Mavigner, M., Sampey, G. C., Brooks, A. D., Spagnuolo, R. A., Irlbeck, D. M., Mattingly, C., Ho, P. T., Schoof, N., Cammon, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-1951-3 · Cited by 299
Li, J. Z., Etemad, B., Ahmed, H., Aga, E., Bosch, R. J., Mellors, J. W., Kuritzkes, D. R., Lederman, M. M., Para, M., & Gandhi, R. T. (2015) · AIDS · doi:10.1097/qad.0000000000000953 · Cited by 287
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
Singh, K. P., Crane, M., Audsley, J., Avihingsanon, A., Sasadeusz, J., & Lewin, S. R. (2017) · AIDS · doi:10.1097/qad.0000000000001574 · Cited by 268
Self-citationElliott, J. H., McMahon, J. H., Chang, C. C., Lee, S. A., Hartogensis, W., Bumpus, N., Savic, R., Roney, J., Hoh, R., Solomon, A., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00226-x · Cited by 250
Self-citationAit-Ammar, A., Kula, A., Darcis, G., Verdikt, R., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Rohr, O., & Van Lint, C. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03060 · Cited by 163
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Efficient mRNA delivery to resting T cells to reverse HIV latency
Cevaal, P. M., Kan, S., Fisher, B. M., Moso, M. A., Tan, A., Liu, H., Ali, A., Tanaka, K., Shepherd, R. A., Kim, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60001-2 · Cited by 38
Self-citationAnalysis of the effect of HDAC inhibitors on the formation of the HIV reservoir
Ling, L., Kim, M., Soper, A., Kovarova, M., Spagnuolo, R. A., Begum, N., Kirchherr, J., Archin, N., Battaglia, D., Cleveland, D., et al. (2024) · mBio · doi:10.1128/mbio.01632-24 · Cited by 14
Gallego-Cortés, A., Sánchez-Gaona, N., Mancebo-Pérez, C., Ruiz-Isant, O., Benítez-Martínez, A., Landolfi, S., Castellví, J., Pumarola, F., Ortiz, N., Llano, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65288-9 · Cited by 12
Chang, L.-C., Yin, M. T., Laird, G. M., Ritter, K. D., Shah, J. G., & Debnath, A. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062772 · Cited by 3
Metadata
- Authors
- Elliott, J. H., Wightman, F., Solomon, A., Ghneim, K., Ahlers, J., Cameron, M. J., Smith, M. Z., Spelman, T., McMahon, J., Velayudham, P., Brown, G., Roney, J., Watson, J., Prince, M. H., Hoy, J. F., Chomont, N., Fromentin, R., Procopio, F. A., Zeidan, J., Palmer, S., Odevall, L., Johnstone, R. W., Martin, B. P., Sinclair, E., Deeks, S. G., Hazuda, D. J., Cameron, P. U., Sékaly, R.-P., & Lewin, S. R.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-11-13
- Volume
- 10
- Issue
- 11
- Pages
- e1004473
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W1971112771
- Cited by
- 504
- References
- 61
- FWCI
- 21.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.